Advertisement
Advertisement
LEGN
Legend Biotech Corporation - ADR
19.14
USDSponsored
+0.09
+0.49%
Apr 02, 15:59 UTC -4
Closed
After-Market
19.14
0.00
+0.01%
LEGN Earnings Reports
Positive Surprise Ratio
LEGN beat 9 of 21 last estimates.
43%
Next Report
Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
$311.36M
/-$0.02
Implied change from Q4 25 (Revenue/ EPS)
+1.65%
/-87.50%
Implied change from Q1 25 (Revenue/ EPS)
+59.63%
/-96.30%
Legend Biotech Corporation - ADR earnings per share and revenue
On Mar 10, 2026, LEGN reported earnings of -0.16 USD per share (EPS) for Q4 25, missing the estimate of -0.11 USD, resulting in a -44.53% surprise. Revenue reached 306.30 million, compared to an expected 313.01 million, with a -2.14% difference. The market reacted with a +2.19% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 7 analysts forecast an EPS of -0.02 USD, with revenue projected to reach 311.36 million USD, implying an decrease of -87.50% EPS, and increase of 1.65% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Nanobiotix S.A. - ADR
Report Date
Mar 31, 2026 For Q4 25
Estimate
$0.55
Actual
-$0.39
Surprise
-170.16%
Forte Biosciences, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.23
Actual
-$1.39
Surprise
-12.31%
Connect Biopharma Holdings Limited Ordinary Shares
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.44
Actual
-$1.91
Surprise
-32.66%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
Fortress Biotech, Inc.
Report Date
Mar 31, 2026 For Q4 25
Estimate
$0.11
Actual
-$0.01
Surprise
-108.91%
MiNK Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.83
Actual
-$0.55
Surprise
+33.64%
Cadrenal Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.18
Actual
-$1.43
Surprise
-20.34%
BioAtla, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.24
Actual
-$0.16
Surprise
+34.64%
Cyclerion Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.38
Actual
-$0.21
Surprise
+45.82%
FAQ
What were Legend Biotech Corporation - ADR's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Legend Biotech Corporation - ADR reported EPS of -$0.16, missing estimates by -44.53%, and revenue of $306.30M, -2.14% below expectations.
How did the market react to Legend Biotech Corporation - ADR's Q4 2025 earnings?
The stock price moved up 2.19%, changed from $19.14 before the earnings release to $19.56 the day after.
When is Legend Biotech Corporation - ADR expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for Legend Biotech Corporation - ADR's next earnings report?
Based on 7
analysts, Legend Biotech Corporation - ADR is expected to report EPS of -$0.02 and revenue of $311.36M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement